Effective October 30, 2020, clinical trials sponsored by the National Institute of Allergy and Infectious Disease (NIAID) will be covered for the treatment and prevention of COVID-19. This change is effective for the duration of the president’s national emergency regarding COVID-19; however, if a beneficiary has been enrolled in a NIAID-sponsored trial during the national emergency, they will continue to have their cost shared for the duration of the trial, even if the public health emergency has ended.
